MX357759B - Formulaciones y formas de dosificacion de fosfolipidos oxidados. - Google Patents

Formulaciones y formas de dosificacion de fosfolipidos oxidados.

Info

Publication number
MX357759B
MX357759B MX2014002362A MX2014002362A MX357759B MX 357759 B MX357759 B MX 357759B MX 2014002362 A MX2014002362 A MX 2014002362A MX 2014002362 A MX2014002362 A MX 2014002362A MX 357759 B MX357759 B MX 357759B
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
formulations
dosage forms
oxidized phospholipids
capsules
Prior art date
Application number
MX2014002362A
Other languages
English (en)
Other versions
MX2014002362A (es
Inventor
Sher Naamit
M Young Victor
Mcnaughton Alyn
Bakhshaee Massoud
Robert Wilding Ian
Original Assignee
Vascular Biogenics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vascular Biogenics Ltd filed Critical Vascular Biogenics Ltd
Publication of MX2014002362A publication Critical patent/MX2014002362A/es
Publication of MX357759B publication Critical patent/MX357759B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción provee composiciones farmacéuticas con un fosfolípido oxidado, tal como 1- hexadecil-2- (4´ -carboxibutil) -glicero-3-fosfocolina (VB-201) y un portador termoplástico, por ejemplo, a poloxámero. Las composiciones farmacéuticas además pueden comprender un agente anti-adherente, tal como talco y/o un agente tixotrópico. La presente descripción además provee procesos para preparar las composiciones farmacéuticas. La descripción además provee cápsulas con las composiciones farmacéuticas. Los usos de tales composiciones farmacéuticas y cápsulas en el tratamiento de trastornos inflamatorios también se describen.
MX2014002362A 2011-09-01 2012-08-31 Formulaciones y formas de dosificacion de fosfolipidos oxidados. MX357759B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161529989P 2011-09-01 2011-09-01
PCT/US2012/053533 WO2013033642A1 (en) 2011-09-01 2012-08-31 Formulations and dosage forms of oxidized phospholipids

Publications (2)

Publication Number Publication Date
MX2014002362A MX2014002362A (es) 2014-04-30
MX357759B true MX357759B (es) 2018-07-24

Family

ID=46964020

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002362A MX357759B (es) 2011-09-01 2012-08-31 Formulaciones y formas de dosificacion de fosfolipidos oxidados.

Country Status (16)

Country Link
US (3) US9254297B2 (es)
EP (1) EP2750668B1 (es)
JP (1) JP6109175B2 (es)
KR (1) KR101939430B1 (es)
CN (1) CN103874485B (es)
AU (1) AU2012301602B2 (es)
BR (1) BR112014004916B1 (es)
CA (1) CA2847218C (es)
EA (1) EA029274B1 (es)
ES (1) ES2768266T3 (es)
HK (1) HK1198430A1 (es)
IL (1) IL231222B (es)
MX (1) MX357759B (es)
SG (1) SG11201400208PA (es)
WO (1) WO2013033642A1 (es)
ZA (1) ZA201401478B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US7807847B2 (en) 2004-07-09 2010-10-05 Vascular Biogenics Ltd. Process for the preparation of oxidized phospholipids
US9006217B2 (en) 2007-01-09 2015-04-14 Vascular Biogenics Ltd. High-purity phospholipids
US8569529B2 (en) 2007-01-09 2013-10-29 Vascular Biogenics Ltd. High-purity phospholipids
EP2348864A4 (en) 2008-10-08 2013-07-31 Vascular Biogenics Ltd OXIDIZED THIOPHOSPHOLIPID COMPOUNDS AND USES THEREOF
JP5752599B2 (ja) 2008-11-06 2015-07-22 ヴァスキュラー バイオジェニックス リミテッド 酸化脂質化合物およびその使用
EA029274B1 (ru) 2011-09-01 2018-03-30 Васкьюлар Байодженикс Лтд. Препараты и лекарственные формы на основе окисленных фосфолипидов
ES2855299T3 (es) 2014-11-26 2021-09-23 Vascular Biogenics Ltd Lípidos oxidados y tratamiento o prevención de la fibrosis
US9771385B2 (en) 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids
US9540588B2 (en) * 2014-12-16 2017-01-10 Polymer Ventures Inc. Oil recovery aid
US10597603B2 (en) 2014-12-16 2020-03-24 Polymer Ventures, Inc. Oil recovery aid
JP6755530B2 (ja) * 2016-09-02 2020-09-16 国立大学法人岩手大学 皮膚炎の予防又は治療用医薬組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1572226A (en) * 1977-11-03 1980-07-30 Hoechst Uk Ltd Pharmaceutical preparations in solid unit dosage form
US4970233A (en) * 1987-08-04 1990-11-13 Mchugh John E Treatment of Acquired Immunodeficiency Syndrome (AIDS) HTLV-111/LAV infections and Acquired Immunodeficiency Syndroms (AIDS) Related Complex (ARC)
US6333348B1 (en) * 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
US20030188756A1 (en) * 2002-08-19 2003-10-09 Cantorna Margherita T Treatment of inflammatory bowel disease with vitamin d compounds
JP4162486B2 (ja) 2000-11-24 2008-10-08 ヴァスキュラー バイオジェニックス リミテッド アテローム性動脈硬化を防止および処置するための規定された酸化型リン脂質を用いる方法およびそのような酸化型リン脂質を含有する組成物
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
CN1501810A (zh) 2001-01-04 2004-06-02 包含硬化斑相关分子的组合物和用于预防和治疗动脉粥样硬化的方法
WO2004039308A2 (en) * 2002-10-31 2004-05-13 State Of Israel, Ministry Of Agriculture Quinazolinone compositions for regulation of gene expression related to pathological processes
US20060068015A1 (en) * 2003-10-10 2006-03-30 Per Holm Solid dosage form comprising a fibrate and a statin
US7807847B2 (en) 2004-07-09 2010-10-05 Vascular Biogenics Ltd. Process for the preparation of oxidized phospholipids
EP2574612A1 (en) 2004-07-09 2013-04-03 Vascular Biogenics Ltd. Improved process for the preparation of oxidized phospholipids
US8569529B2 (en) 2007-01-09 2013-10-29 Vascular Biogenics Ltd. High-purity phospholipids
EP2348864A4 (en) * 2008-10-08 2013-07-31 Vascular Biogenics Ltd OXIDIZED THIOPHOSPHOLIPID COMPOUNDS AND USES THEREOF
JP5752599B2 (ja) * 2008-11-06 2015-07-22 ヴァスキュラー バイオジェニックス リミテッド 酸化脂質化合物およびその使用
JP2013516455A (ja) 2010-01-05 2013-05-13 バスキュラー バイオジェニックス リミテッド Ｖｂ−２０１を用いた治療
EA029274B1 (ru) * 2011-09-01 2018-03-30 Васкьюлар Байодженикс Лтд. Препараты и лекарственные формы на основе окисленных фосфолипидов

Also Published As

Publication number Publication date
ZA201401478B (en) 2016-09-28
CA2847218C (en) 2018-02-27
WO2013033642A1 (en) 2013-03-07
AU2012301602B2 (en) 2015-09-03
HK1198430A1 (en) 2015-04-24
US20190008880A1 (en) 2019-01-10
US20160220590A1 (en) 2016-08-04
IL231222B (en) 2018-01-31
MX2014002362A (es) 2014-04-30
BR112014004916B1 (pt) 2021-12-21
EP2750668A1 (en) 2014-07-09
EA029274B1 (ru) 2018-03-30
CA2847218A1 (en) 2013-03-07
SG11201400208PA (en) 2014-03-28
CN103874485B (zh) 2017-06-09
US9254297B2 (en) 2016-02-09
AU2012301602A1 (en) 2013-05-02
KR101939430B1 (ko) 2019-01-16
BR112014004916A2 (pt) 2017-04-04
JP2014525463A (ja) 2014-09-29
NZ621710A (en) 2015-10-30
JP6109175B2 (ja) 2017-04-05
EP2750668B1 (en) 2019-12-11
US20130209555A1 (en) 2013-08-15
IL231222A0 (en) 2014-04-30
CN103874485A (zh) 2014-06-18
KR20140078641A (ko) 2014-06-25
EA201490544A1 (ru) 2014-08-29
ES2768266T3 (es) 2020-06-22

Similar Documents

Publication Publication Date Title
MX357759B (es) Formulaciones y formas de dosificacion de fosfolipidos oxidados.
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
PH12014501469A1 (en) Bromodomain inhibitors
MX2013001677A (es) Formulaciones estables de linaclotida.
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
MX2015012006A (es) Inhibidores de bromodominio tetraciclicos.
MX2010010647A (es) Proceso para preparar formulaciones de dabigatran para administracion oral.
TN2012000126A1 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
MY168791A (en) Carbamate compounds and of making and using same
MX2018012161A (es) Lipidos y composiciones novedosas para el suministro de terapeuticos.
EP2576578A4 (en) POLYMORPHES OF 2'-O-FUCOSYLLACTOSE AND MANUFACTURE THEREOF
WO2012054500A3 (en) Compositions for drug administration
TN2012000392A1 (en) Oral formulations and lipophilic salts of methylnaltrexone
IL222578A0 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
MX344787B (es) Composiciones que contienen berberina o analogos de la misma para tratar rosacea o trastornos de la piel relacionados con enrojecimiento de la cara.
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
WO2013003827A3 (en) Macrogol 15 hydroxystearate formulations
MX2015004604A (es) Antagonistas de los receptores metabotropicos de glutamato 2/3 (mglu2/3) para el tratamiento de los trastornos autistas.
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
IN2014DN06869A (es)
WO2013040227A3 (en) Therapeutic compounds
IN2014DN01619A (es)
MX2014013664A (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxietil)ami no)-2-oxo-n-fenil-1,2-dihidroquinolin-3-carboxamida.
WO2014064652A3 (en) Stable pharmaceutical composition of peginterferon alpha-2b
MX2019012375A (es) Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).

Legal Events

Date Code Title Description
FG Grant or registration